BioCentury
ARTICLE | Clinical News

NeoTherapeutics Phase IIb extension

April 6, 2000 7:00 AM UTC

NEOT began an open-label extension of its ongoing U.S. Phase IIb trial of Neotrofin AIT-082 leteprinim to treat mild to moderate Alzheimer's disease. The extension allows patients who complete the tri...